Activity Overview
TROP2-targeting antibody-drug conjugates (ADCs) provide a critical option for the treatment of patients with non-small cell lung cancer (NSCLC) across multiple lines of therapy. However, the rapidly evolving evidence base for these agents and their distinct toxicity profiles require clinicians to interpret heterogeneous trial designs and engage in multidisciplinary toxicity management.
This webcast focuses on clinical trials investigating the combination of TROP2-targeting ADCs with immunotherapy for the treatment of NSCLC. Case discussions, an overview of trial data, and panel discussions with faculty from across the globe will prepare learners to evaluate frontline combination clinical trial readouts and develop personalized treatment plans for their patients.
This educational activity is an archive of the live presentation held on June 9, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward a global audience of oncology clinicians, including medical oncologists, thoracic oncologists, pulmonologists, advanced practice providers, oncology nurses, pharmacists, and other members of the multidisciplinary cancer care team involved in the management of patients with NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess recent clinical trial and emerging pipeline data for TROP2-targeted ADCs and combination strategies in NSCLC
- Select evidence-informed treatment and sequencing strategies for patients with NSCLC across relevant biomarker subsets
Solange Peters, MD, PhD
Full Professor
Chair of Medical Oncology and Oncology Program
University Hospital of Lausanne
Lausanne, Switzerland
Disclosures: Consultation/Advisory Role (all fees to institution): AbbVie, Amgen, Arcus, AstraZeneca, Bayer, BeiGene, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, BioNTech, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, Eli Lilly, Foundation Medicine, F-Star, Genmab, Genzyme, Gilead, GSK, HUTCHMED, Illumina, Incyte, Ipsen, iTeos, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Novocure, Nuvalent, Nuvation Bio, Nykode Therapeutics, Pfizer, Pharma Mar, Promontory Therapeutics, Qlucore, Regeneron, Roche/Genentech, Sanofi, Takeda, Zymeworks; Speakers Bureau (all fees to institution): AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Foundation Medicine, GSK, Illumina, Ipsen, Merck Sharp & Dohme, Novartis, Pfizer, Roche/Genentech, Sanofi, Takeda; Grant/Research Funding (to institution): Amgen, Arcus, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, iTeos, Merck Sharp & Dohme, Mirati, Pfizer, Pharma Mar, Promontory Therapeutics, Roche/Genentech
Myung-Ju Ahn, MD, PhD
Professor, Section of Hematology-Oncology
Department of Medicine
Hanyang University Medical Center
Hanyang University College of Medicine
Seoul, Korea
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Amgen, AstraZeneca, Bayer, BeOne (BeiGene), BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genmab, Gilead, GSK, Ipsen, Jazz Pharmaceuticals, Johnson & Johnson, Merck Serono, Merck Sharp & Dohme, Mirati Therapeutics, Novartis, Ottimo Pharma, Pfizer, PharmaMar, Pierre Fabre, Regeneron, Roche/Genentech, Sanofi, Takeda; Speakers Bureau: Bristol Myers Squibb, Eli Lilly, Merck Serono, Merck Sharp & Dohme Oncology, Pfizer, Roche/Genentech; Leadership Role: ALTUM sequencing, Stab Therapeutics
Luis Paz-Ares, MD, PhD
Chair, Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Head, Lung Cancer Unit
National Oncology Research Center
Madrid, Spain
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Gilead, Jazz, Medtronic, Merck, Novartis, Pfizer, Sanofi; Grant/Research Funding: Amgen, Harpoon, Novartis
Jacob Sands, MD
Associate Chief, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor, Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Aimed Bio, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Genexine, Merck, MSD, Roche, Takeda, Voronoi
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here